Protalix BioTherapeutics (PLX) Cash from Operations Growth (3y) (2013 - 2026)
Protalix BioTherapeutics (PLX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,899.87 Bn | 1,899.81 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.43 Bn | 465.64 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.43 Bn | 116.19 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.20 Bn | 61.44 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 61.75 Bn | 61.75 Bn | - | - |
| 8 | Argenx Se | 56.15 Bn | 50.96 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | 34.32% |
| 10 | Protalix BioTherapeutics | 195.23 Mn | 184.44 Mn | 29.62 Mn | 110.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 110.64% |
| Dec 31, 2025 | 40.57% |
| Sep 30, 2025 | 25.98% |
| Jun 30, 2025 | 10.73% |
| Mar 31, 2025 | 4.62% |
| Dec 31, 2024 | 40.69% |
| Sep 30, 2024 | 61.13% |
| Jun 30, 2024 | -36.69% |
| Mar 31, 2024 | 34.37% |
| Dec 31, 2023 | 35.29% |
| Sep 30, 2023 | -24.10% |
| Jun 30, 2023 | 38.12% |
| Mar 31, 2023 | 25.04% |
| Dec 31, 2022 | 10.87% |
| Sep 30, 2022 | -41.85% |
| Jun 30, 2022 | -12.47% |
| Mar 31, 2022 | 7.12% |
| Dec 31, 2021 | -8.31% |
| Sep 30, 2021 | -28.82% |
| Jun 30, 2021 | 41.25% |